J&J

Attorneys for Talc Victims Say Dismissal of Second Attempted Bankruptcy by J&J Should Prompt New Trials, Negotiations

Retrieved on: 
Friday, August 11, 2023
Talc, J&J, LTL, Country-western two-step, Woman, Ovarian cancer, Action Replay, Bankruptcy, Injury, Disease, Airline

MONTGOMERY, Ala., Aug. 11, 2023 /PRNewswire/ -- Today's formal dismissal of the second unsuccessful attempt by Johnson & Johnson to seek bankruptcy protection for its LTL Management subsidiary should lead courts to resume scheduling civil trials across the nation, according to attorneys with the Beasley Allen Law Firm.

Key Points: 
  • The firm represents thousands of women who developed ovarian cancer after regular use of J&J's asbestos-tainted talcum powder products.
  • "Tragically, hundreds of women have died during this delay and will never see their day in court.
  • Now our firm can aggressively begin seeking a resumption of the trials that have been on hold for far too long.
  • We stand ready to engage in rational and productive negotiations with J&J to resolve these claims," adds Mr. Birchfield.

TransPerfect Medical Device Solutions Successfully Completes Stringent Johnson & Johnson Supplier Audit

Retrieved on: 
Monday, August 7, 2023
CAPA, IVDR, TransPerfect, PDF, Record, MDS, J&J, MDR, Documentation, PMS, Johnson & Johnson, AI, Automation, Management, Medical device, Encompass

NEW YORK, Aug. 7, 2023 /PRNewswire/ -- TransPerfect Medical Device Solutions (MDS), the world's largest provider of language services and process automation technology to the medical device industry, today announced the successful completion of a stringent supplier requalification audit for industry heavyweight Johnson & Johnson (J&J), with zero findings across the three evaluated categories: critical, major, and minor.

Key Points: 
  • NEW YORK, Aug. 7, 2023 /PRNewswire/ -- TransPerfect Medical Device Solutions (MDS), the world's largest provider of language services and process automation technology to the medical device industry, today announced the successful completion of a stringent supplier requalification audit for industry heavyweight Johnson & Johnson (J&J), with zero findings across the three evaluated categories: critical, major, and minor.
  • The scope of the J&J audit comprised nine different J&J medical device and pharma franchises and 31 different TransPerfect sites, including three primary sites for TransPerfect Medical Device Solutions.
  • The results of the J&J audit serve as a testament to TransPerfect's ongoing dedication to delivering quality and automation for medical device manufacturers.
  • TransPerfect MDS President Marc Miller observed, "J&J was among the first major device makers to run an RFP specifically for the EU Medical Device Regulation (MDR)—and we were honored to be selected as the lead supplier at the time.

Nachawati Law Group Trial Lawyers Renew Commitment to Cancer Victims After Judge’s Rejection of Johnson & Johnson’s Proposed $8.9B Settlement

Retrieved on: 
Monday, July 31, 2023
Class Action Lawsuit, Professional Services, Legal, Talc, J&J, Johnson & Johnson, Cancer, LTL, Woman, JNJ, Ovarian cancer, Internal, NYSE, Bankruptcy, Pharmaceutical industry

U.S. Bankruptcy Judge Michael Kaplan rejected the proposed $8.9 billion settlement tied to a bankruptcy filing by J&J subsidiary LTL Management.

Key Points: 
  • U.S. Bankruptcy Judge Michael Kaplan rejected the proposed $8.9 billion settlement tied to a bankruptcy filing by J&J subsidiary LTL Management.
  • Trial lawyers with Dallas-based Nachawati Law Group have played a key role in bankruptcy litigation against Johnson & Johnson and helped negotiate the most recent proposed settlement.
  • “Our firm respects Judge Kaplan’s decision,” said Nachawati Law Group founder Majed Nachawati , who represents more than 5,000 ovarian cancer victims.
  • Nachawati Law Group represents individuals in mass tort litigation, businesses and governmental entities in contingent litigation, and individual victims in serious personal injury litigation.

Legal-Bay Pre-Settlement Funding to Add Mesothelioma Cases for Funding Along with Talc After Large $18MM Verdict

Retrieved on: 
Monday, July 31, 2023
Talc, Pressure, Justice minister, False Claims Act, Falls, History, Judgement, J&J, Patent, Inferior vena cava, Mesothelioma, Johnson & Johnson, Ovarian cancer, Personal injury, Bankruptcy, Injury, Insurance

TRENTON, N.J., July 31, 2023 /PRNewswire/ -- Legal-Bay, The Pre Settlement Funding Company, announced today that they are now adding mesothelioma victims to their list of Johnson & Johnson talc plaintiffs. The pharmaceutical company just lost their most recent court case, resulting in a landmark $18 million verdict. Both J&J and plaintiffs/lawyers await the next steps in what has been a painfully slow process.

Key Points: 
  • The pharmaceutical company just lost their most recent court case, resulting in a landmark $18 million verdict.
  • While J&J has offered to settle the cases, the amount seems to be a fraction of what juries are awarding in both talc and mesothelioma verdicts of late."
  • Legal-Bay is also funding loans for lawsuits on Round Up cases, Essure, Juul e-Cigarettes, Hernia Mesh, IVC Filters, and Exactech hip and knee recall cases.
  • Their lawsuit loans funding programs are designed to provide immediate cash in advance of a plaintiff's anticipated monetary award.

The Official Committee of Talc Claimants Applauds Decision to Dismiss LTL Management Second Bankruptcy Attempt

Retrieved on: 
Friday, July 28, 2023
Committee, J&J, Official Committee of Equity Security Holders, Texas two-step bankruptcy, Johnson & Johnson, TCC, The Honourable, LTL, United States bankruptcy court, Justice, Bankruptcy, State attorney general

NEW YORK, July 28, 2023 /PRNewswire/ -- The Official Committee of Talc Claimants (the "Committee"), which has been tirelessly pursuing justice for its constituency of talc victims injury by Johnson & Johnson's ("J&J's") talc products, is pleased with the court's decision to dismiss the second bankruptcy attempt.

Key Points: 
  • NEW YORK, July 28, 2023 /PRNewswire/ -- The Official Committee of Talc Claimants (the "Committee"), which has been tirelessly pursuing justice for its constituency of talc victims injury by Johnson & Johnson's ("J&J's") talc products, is pleased with the court's decision to dismiss the second bankruptcy attempt.
  • We believe the decision of the Honorable Chief Judge Kaplan was thoughtful, well-reasoned, and well-supported by the facts and law.
  • The Committee has consistently contended the tort system is the rightful place for these claims to be resolved.
  • Untold numbers  of cancer victims have died while Johnson & Johnson attempted to manipulate the bankruptcy system to limit its liabilities," added Molton.

The Official Committee of Talc Claimants Applauds Decision to Dismiss LTL Management Second Bankruptcy Attempt

Retrieved on: 
Friday, July 28, 2023
Committee, J&J, Official Committee of Equity Security Holders, Texas two-step bankruptcy, Johnson & Johnson, TCC, The Honourable, LTL, United States bankruptcy court, Justice, Bankruptcy, State attorney general

NEW YORK, July 28, 2023 /PRNewswire/ -- The Official Committee of Talc Claimants (the "Committee"), which has been tirelessly pursuing justice for its constituency of talc victims' injury by Johnson & Johnson's ("J&J's") talc products, is pleased with the court's decision to dismiss the second bankruptcy attempt.

Key Points: 
  • NEW YORK, July 28, 2023 /PRNewswire/ -- The Official Committee of Talc Claimants (the "Committee"), which has been tirelessly pursuing justice for its constituency of talc victims' injury by Johnson & Johnson's ("J&J's") talc products, is pleased with the court's decision to dismiss the second bankruptcy attempt.
  • We believe the decision of the Honorable Chief Judge Kaplan was thoughtful, well-reasoned, and well-supported by the facts and law.
  • The Committee has consistently contended the tort system is the rightful place for these claims to be resolved.
  • Untold numbers of cancer victims have died while Johnson & Johnson attempted to manipulate the bankruptcy system to limit its liabilities," added Molton.

BD Names Joanne Waldstreicher to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Bioethics, Endocrinology, Internal medicine, Ronald Reagan Presidential Library, University School, Health, Research, Medicine, Jeff Waldstreicher, Merck & Co., Harvard Medical School, J&J, Becton, Dickinson and Company headquarters, Chemistry, Development, Retirement, Publication, Beth Israel Hospital, Metabolism, Division, Population health, Medical ethics, Hospital, Johnson & Johnson, Becton, Biostatistics, FDA, Massachusetts General Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Epidemiology, BDX, NYSE, Medtech, Food, Safety, BD, Management, Pharmaceutical industry, Brooklyn College

FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors.

Key Points: 
  • FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors.
  • Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023.
  • Prior to being named chief medical officer for J&J, Waldstreicher served as chief medical officer for Janssen Pharmaceutical Research and Development, which is a division of J&J, from 2009 to 2012.
  • Waldstreicher earned a bachelor's degree in chemistry from Brooklyn College and her doctor of medicine from Harvard Medical School.

Dana Foundation Appoints Two New Board Members

Retrieved on: 
Tuesday, July 18, 2023
Brain, Council, Bangladesh Technical Education Board, J&J, Manji, National Academy of Medicine, Foreign policy, University of Oxford, University, Therapy, Policy, Television, NAM, Government, Meredith Corporation, Organization, Biomarker, Smithsonian Institution, UK, NIH, International Academy of Television Arts and Sciences, PBS, Foundation (nonprofit), Professional corporation, Humanities, Multimedia, History, Nature, Dana Foundation, Publication, International Academy, Ethics, Johnson & Johnson, Women's Forum for the Economy & Society, National academy, Education, American Academy, Natural history, FRCPC, National Museum of Natural History, Nursing, Management, Pharmaceutical industry, Science, Neuroscience, Behavior

NEW YORK, July 18, 2023 /PRNewswire/ -- The Dana Foundation is pleased to announce the addition of two members to its board of directors: Paula A. Kerger and Husseini Manji, M.D., FRCPC.

Key Points: 
  • New Members Bring Expertise in Media, Education, Neuroscience, and Technology
    NEW YORK, July 18, 2023 /PRNewswire/ -- The Dana Foundation is pleased to announce the addition of two members to its board of directors: Paula A. Kerger and Husseini Manji, M.D., FRCPC.
  • "The Board is delighted to welcome two extremely distinguished and highly effective new directors to its ranks," said Steven E. Hyman, M.D., chairman of the Dana Foundation.
  • "Our newly elected board members each bring unique perspectives from different fields and organizations, which will enrich the interdisciplinary focus of the Dana Foundation," said Caroline Montojo, Ph.D., president of the Dana Foundation.
  • Kerger and Manji will join the following Dana Foundation board members: Steven E. Hyman, Edward Bleier, Wallace L. Cook, Charles A. Dana III, Hildegarde E. Mahoney, and Peter A. Nadosy.

J&J-Stop TB Partnership Deal a Positive Step but More Is Needed, says AHF

Retrieved on: 
Saturday, July 15, 2023
Infectious Diseases, Pharmaceutical, AIDS, Health, TB, AHF, J&J, COVID-19, Policy, Hope, Stop TB Partnership, Death, HIV, AIDS Healthcare Foundation, Pharmaceutical industry

With Johnson and Johnson (J&J) recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries, AIDS Healthcare Foundation ( AHF ) applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement.

Key Points: 
  • With Johnson and Johnson (J&J) recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries, AIDS Healthcare Foundation ( AHF ) applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement.
  • While the deal is a positive step, AHF agrees with advocates, including Médecins Sans Frontières and others, that this is a short-term solution and urges J&J to do more for other lower-income countries that still lack access.
  • “Tuberculosis kills 1.6 million people annually and remains the leading cause of death for people living with HIV.
  • It is being reported that countries in Eastern Europe and Central Asia, which have some of the world’s highest burden of drug-resistant TB, are left out of the deal.

SonoThera™ Expands Leadership Team Appointing Carolyne Zimmermann as Chief Business Officer

Retrieved on: 
Tuesday, June 27, 2023
Columbia University, University of California, San Diego, Engineering, Business development, Partnership, University, Carolyne, Centre for India & Global Business, Searching, Biotechnology, General partnership, Columbia Business School, AAV, Doctor of Philosophy, Transaction, J&J, Gene, Business administration, Novartis, Acquisition, Investment, Evaluation, SAN, Disease, Johnson & Johnson, Therapy, Pharmaceutical industry, Qualcomm, Negotiation

SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced the expansion of its leadership team with the appointment of Carolyne Zimmermann as its Chief Business Officer.

Key Points: 
  • SAN FRANCISCO, June 27, 2023 /PRNewswire/ -- SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases through genetic therapy, today announced the expansion of its leadership team with the appointment of Carolyne Zimmermann as its Chief Business Officer.
  • "We are thrilled to have Carolyne join our team at SonoThera," said Kenneth Greenberg, PhD, co-founder, and chief executive officer of SonoThera™.
  • Ms. Zimmermann was most recently Chief Business Officer for 4D Molecular Therapeutics (4DMT), an emerging clinical stage AAV gene therapy company.
  • Ms. Zimmermann spent 14 years at Novartis Pharmaceuticals as a member of the Global Business Development Leadership Team, serving in numerous leadership roles in business development functions such as Search & Evaluation, Negotiations, and Alliance Management across several of Novartis' therapeutic areas.